Collegium Pharmaceutical, Inc.
COLL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1 | $1 | $0 | $0 |
| % Growth | 11.4% | 22.2% | 67.6% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 59.8% | 57.5% | 45.2% | 54.4% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | $0 | $0 | $0 | $0 |
| % Margin | 26.9% | 29.5% | 7.2% | 6.4% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | $0 | $0 | -$0 | -$0 |
| Tax Expense | $0 | $0 | -$0 | -$0 |
| Net Income | $0 | $0 | -$0 | $0 |
| % Margin | 11% | 8.5% | -5.4% | 25.8% |
| EPS | 2.14 | 1.6 | -0.74 | 2.05 |
| % Growth | 33.8% | 316.2% | -136.1% | – |
| EPS Diluted | 1.86 | 1.29 | -0.74 | 1.86 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 54.1% | 54.4% | 37.4% | 31.3% |